Home > News > Big Pharma Is Missing the Nanotechnology Opportunity
February 15th, 2005
Big Pharma Is Missing the Nanotechnology Opportunity
Abstract:
The U.S. National Institutes of Health counts nanomedicine as one of its top five priorities, the National Cancer Institute committed $144 million to nanotechnology research in October 2004, and 40% of nanotech venture capital since 1998 has gone to life sciences start-ups. Yet despite nanotechnology's promise in improving how drugs are developed and delivered, major pharmaceutical companies are committing almost
no money or people to nanotechnology research -- exposing them to strategic
risks, according to a new report from Lux Research entitled "Why Big Pharma Is
Missing the Nanotech Opportunity."
Source:
prnewswire
Bookmark:
| Related News Press |
Nanomedicine
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Good as gold - improving infectious disease testing with gold nanoparticles April 5th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||